Bleximenib and Venclexta treatment were well tolerated in a phase 1b trial for relapsed/refractory acute myeloid leukemia with mostly low-grade side effects. Treatment with bleximenib and Venclexta ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback